Published in Future Oncol on January 01, 2014
Addressing phenoconversion: the Achilles' heel of personalized medicine. Br J Clin Pharmacol (2015) 0.90
The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients. Int J Mol Sci (2015) 0.85
Tamoxifen Resistance: Emerging Molecular Targets. Int J Mol Sci (2016) 0.80
Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance. Sci Rep (2016) 0.79
Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer. Breast Cancer Res Treat (2014) 0.77
Tamoxifen Treatment of Breast Cancer Cells: Impact on Hedgehog/GLI1 Signaling. Int J Mol Sci (2016) 0.77
CYP1A2 - a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients. BMC Cancer (2016) 0.76
Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. BMJ (2016) 0.75
Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity. Am J Epidemiol (2016) 0.75
CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset. Sci Rep (2017) 0.75
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (2011) 10.62
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol (2009) 9.18
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst (2005) 7.70
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst (2012) 5.27
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
Tamoxifen in the treatment of breast cancer. N Engl J Med (1998) 4.75
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ (2010) 4.73
Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol (2009) 4.70
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat (2004) 3.40
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol (2007) 3.36
Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol (2005) 3.34
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol (2010) 3.21
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol (1977) 3.03
Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat (2005) 2.75
Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol (2010) 2.61
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res (2005) 2.48
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol (2005) 2.41
Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol (2001) 2.36
Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet (2005) 2.21
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res (2007) 2.20
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol (2010) 2.15
Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci (2008) 1.95
Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol (2008) 1.92
CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned. J Natl Cancer Inst (2012) 1.81
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol (1992) 1.71
Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am J Epidemiol (2006) 1.67
Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol (2009) 1.65
Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst (2005) 1.60
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol (1996) 1.60
Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol (2007) 1.55
Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer (2008) 1.50
Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res Treat (1982) 1.48
CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst (2011) 1.47
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst (2012) 1.46
Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res (1988) 1.45
The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics (2010) 1.44
Immortal person-time in studies of cancer outcomes. J Clin Oncol (2009) 1.40
Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics (2003) 1.39
Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol (1997) 1.37
The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat (2009) 1.34
Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. Clin Cancer Res (2001) 1.34
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res (2012) 1.33
Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat (2007) 1.31
CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res (2010) 1.31
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst (2012) 1.30
Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res (2008) 1.28
The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol (2002) 1.28
Tamoxifen as an anti-tumour agent: effect on oestrogen binding. J Endocrinol (1976) 1.27
Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat (2009) 1.25
Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat (2012) 1.23
Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer (2008) 1.22
Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol (2010) 1.21
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 1.20
High-throughput loss of heterozygosity mapping in 26 commonly deleted regions in breast cancer. Cancer Epidemiol Biomarkers Prev (2003) 1.20
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat (2009) 1.20
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat (2010) 1.18
Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Semin Oncol (2005) 1.14
Chromosome 22 array-CGH profiling of breast cancer delimited minimal common regions of genomic imbalances and revealed frequent intra-tumoral genetic heterogeneity. Int J Oncol (2006) 1.09
Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res (2005) 1.07
Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol (2010) 1.07
No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev (2009) 1.06
Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue. Clin Epidemiol (2010) 1.06
Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells. Endocr Relat Cancer (2007) 1.06
Discovery of complex pathways from observational data. Stat Med (2010) 1.02
No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment. Jpn J Clin Oncol (2009) 1.01
Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol (2005) 0.98
Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition. J Clin Pharmacol (2004) 0.98
The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer (2004) 0.98
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen. Ann N Y Acad Sci (2009) 0.98
Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1). Drug Metab Dispos (2010) 0.94
Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest (1979) 0.93
CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients. Pharmgenomics Pers Med (2012) 0.93
Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res (2010) 0.92
Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010. Breast Cancer Res Treat (2012) 0.92
P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration. J Pharmacol Exp Ther (2011) 0.91
The metabolism of tamoxifen in human. Biochem Pharmacol (1979) 0.90
Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. Breast Cancer Res Treat (2013) 0.89
Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat (2010) 0.89
Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial. Int J Mol Epidemiol Genet (2010) 0.88
The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1. AAPS J (2011) 0.88
Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand. Asian Pac J Cancer Prev (2012) 0.87
Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality. Future Oncol (2010) 0.86
Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment. Curr Med Res Opin (2010) 0.86
Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development. Expert Opin Drug Metab Toxicol (2012) 0.84
Association between CYP2D6 polymorphisms and breast cancer outcomes. JAMA (2010) 0.84
Effect of CYP2D6 polymorphisms on breast cancer recurrence. Cancer (2011) 0.83
Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy. Cancer Chemother Pharmacol (2012) 0.83
Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. J Korean Med Sci (2011) 0.82
Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population. Drug Metab Pharmacokinet (2008) 0.82
Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res Treat (2010) 0.81
A method to automate probabilistic sensitivity analyses of misclassified binary variables. Int J Epidemiol (2005) 5.17
The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol (2011) 4.54
Breast cancer treatment of older women in integrated health care settings. J Clin Oncol (2006) 3.46
Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol (2007) 3.42
Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg (2007) 2.43
A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol (2009) 2.33
Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst (2011) 2.27
Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res (2009) 2.23
Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes. Am J Physiol Regul Integr Comp Physiol (2002) 2.23
Use of penicillin and other antibiotics and risk of multiple sclerosis: a population-based case-control study. Am J Epidemiol (2011) 2.12
[Medical treatment of depression during pregnancy and breastfeeding]. Ugeskr Laeger (2007) 2.08
Recurrences and second primary breast cancers in older women with initial early-stage disease. Cancer (2007) 1.94
Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. Hepatology (2006) 1.87
Breast cancer in older women: quality of life and psychosocial adjustment in the 15 months after diagnosis. J Clin Oncol (2003) 1.85
Acute stress reaction and completed suicide. Int J Epidemiol (2010) 1.82
Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer. J Clin Oncol (2002) 1.75
Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol (2010) 1.66
Under utilization of surveillance mammography among older breast cancer survivors. J Gen Intern Med (2007) 1.65
What's wrong with the National Ambient Air Quality Standard (NAAQS) for fine particulate matter (PM(2.5))? Regul Toxicol Pharmacol (2002) 1.59
Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev (2010) 1.55
The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics (2011) 1.52
Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer (2005) 1.50
The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. Thromb Haemost (2005) 1.46
Predictors of timely follow-up after abnormal cancer screening among women seeking care at urban community health centers. Cancer (2010) 1.46
Immortal person-time in studies of cancer outcomes. J Clin Oncol (2009) 1.40
If you want to know the end, look at the beginning. Epidemiology (2015) 1.39
Validity of birth certificate-derived maternal weight data. Paediatr Perinat Epidemiol (2014) 1.39
Posttraumatic stress disorder and cancer risk: a nationwide cohort study. Eur J Epidemiol (2015) 1.39
First trimester in utero exposure to methylphenidate. Basic Clin Pharmacol Toxicol (2013) 1.38
Automated inter-rater reliability assessment and electronic data collection in a multi-center breast cancer study. BMC Med Res Methodol (2007) 1.36
Comorbidity and survival of Danish cirrhosis patients: a nationwide population-based cohort study. Hepatology (2008) 1.28
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol (2013) 1.26
Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer (2009) 1.25
Validation of spontaneous abortion diagnoses in the Danish National Registry of Patients. Clin Epidemiol (2010) 1.16
Posttraumatic stress disorder and completed suicide. Am J Epidemiol (2010) 1.14
Increased CUG triplet repeat-binding protein-1 predisposes to impaired adipogenesis with aging. J Biol Chem (2006) 1.13
Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol (2006) 1.13
Obesity in young men, and individual and combined risks of type 2 diabetes, cardiovascular morbidity and death before 55 years of age: a Danish 33-year follow-up study. BMJ Open (2013) 1.13
Effect of undertreatment on the disparity in age-related breast cancer-specific survival among older women. Breast Cancer Res Treat (2006) 1.12
Validity of self-reported rheumatoid arthritis in a large cohort: results from the Black Women's Health Study. Arthritis Care Res (Hoboken) (2010) 1.07
Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study. Breast Cancer Res (2008) 1.07
The relative bioavailability of loratadine administered as a chewing gum formulation in healthy volunteers. Eur J Clin Pharmacol (2006) 1.07
Impact of acquired comorbidities on all-cause mortality rates among older breast cancer survivors. Med Care (2009) 1.07
No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev (2009) 1.06
Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue. Clin Epidemiol (2010) 1.06
Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy. J Clin Oncol (2010) 1.06
Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J Natl Cancer Inst (2012) 1.04
Breast cancer survival of American Indian/Alaska Native women, 1973-1996. Soz Praventivmed (2005) 1.03
Increased TNFalpha and CCAAT/enhancer-binding protein homologous protein with aging predispose preadipocytes to resist adipogenesis. Am J Physiol Endocrinol Metab (2007) 1.01
Alcohol and breastfeeding. Basic Clin Pharmacol Toxicol (2013) 0.99
Survival in Danish patients with breast cancer and inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis (2008) 0.99
Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol (2011) 0.98
A null association between smoking during pregnancy and breast cancer using Massachusetts registry data (United States). Cancer Causes Control (2003) 0.98
Determinants and patterns of utilization of primary percutaneous coronary intervention across 12 European countries: 2003-2008. Int J Cardiol (2013) 0.97
Superficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancer. Eur J Cancer (2011) 0.97
Re: "Neighborhood environment and loss of physical function in older adults: evidence from the Alameda County Study". Am J Epidemiol (2003) 0.96
Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer. Basic Clin Pharmacol Toxicol (2011) 0.96
Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol (2005) 0.95
Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol (2004) 0.95
Comorbid diseases interact with breast cancer to affect mortality in the first year after diagnosis--a Danish nationwide matched cohort study. PLoS One (2013) 0.94
Severe stress and adjustment disorder diagnoses in the population of Denmark. J Trauma Stress (2014) 0.94
Breast cancer recurrence in older women five to ten years after diagnosis. Cancer Epidemiol Biomarkers Prev (2009) 0.94
Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. J Clin Oncol (2013) 0.94
A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet Genomics (2013) 0.93
Correspondence between general practitioner-reported medication use and timing of prescription dispensation. Clin Epidemiol (2012) 0.93
Delayed radiotherapy for breast cancer patients in integrated delivery systems. Am J Manag Care (2009) 0.92
Correcting for exposure misclassification using survival analysis with a time-varying exposure. Ann Epidemiol (2012) 0.92
Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes. Expert Rev Clin Pharmacol (2011) 0.91
Use of SSRIs among Danish children: a nationwide study. Eur Child Adolesc Psychiatry (2014) 0.90
Modification of tamoxifen response: what have we learned? J Clin Oncol (2008) 0.89
Risk of decline in upper-body function and symptoms among older breast cancer patients. J Gen Intern Med (2006) 0.89
Heart disease may be a risk factor for pulmonary embolism without peripheral deep venous thrombosis. Circulation (2011) 0.89
Specifying exposure classification parameters for sensitivity analysis: family breast cancer history. Clin Epidemiol (2009) 0.89
The association between adjustment disorder diagnosed at psychiatric treatment facilities and completed suicide. Clin Epidemiol (2010) 0.89
Five-year mortality in colorectal cancer patients with ulcerative colitis or Crohn's disease: a nationwide population-based cohort study. Inflamm Bowel Dis (2013) 0.89
Trends in breast-conserving surgery in Denmark, 1982-2002. Eur J Epidemiol (2007) 0.88
Lifetime tobacco smoke exposure and breast cancer incidence. Cancer Causes Control (2009) 0.87
The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide. Br J Clin Pharmacol (2006) 0.87
Hospitalization with acute exacerbation of chronic obstructive pulmonary disease and associated health resource utilization: a population-based Danish cohort study. J Med Econ (2013) 0.87
CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel. Clin Exp Pharmacol Physiol (2014) 0.86
Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study. Breast Cancer Res (2012) 0.86
Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality. Future Oncol (2010) 0.86
Persistent geographical disparities in the use of primary percutaneous coronary intervention in 120 European regions: exploring the variation. EuroIntervention (2013) 0.86
A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4. Epilepsia (2007) 0.86
The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects. Br J Clin Pharmacol (2006) 0.86
Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study. Breast Cancer Res (2010) 0.85
Obesity as a risk factor for severe influenza-like illness. Influenza Other Respir Viruses (2013) 0.85
Long-term surveillance mammography and mortality in older women with a history of early stage invasive breast cancer. Breast Cancer Res Treat (2013) 0.85
Effectiveness of adjuvant tamoxifen therapy among older women with early stage breast cancer. Breast J (2007) 0.85
Trauma, comorbidity, and mortality following diagnoses of severe stress and adjustment disorders: a nationwide cohort study. Am J Epidemiol (2015) 0.84
Predictors and outcomes of surgeons' referral of older breast cancer patients to medical oncologists. Cancer (2005) 0.84
Caffeine N3-demethylation (CYP1A2) in a population with an increased exposure to polychlorinated biphenyls. Eur J Clin Pharmacol (2006) 0.84
Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin Pharmacol Ther (2005) 0.84
Long-term statin use and the risk of gallstone disease: A population-based case-control study. Am J Epidemiol (2010) 0.84
Association between CYP2D6 polymorphisms and breast cancer outcomes. JAMA (2010) 0.84
The primary care pediatrician's influence on medical student's performance of smoking assessments and counseling. Prev Med (2004) 0.84
First-trimester exposure to methylphenidate: a population-based cohort study. J Clin Psychiatry (2014) 0.84
Use of antibiotics in children: a Danish nationwide drug utilization study. Pediatr Infect Dis J (2015) 0.83
Mobile phone use and risk of uveal melanoma: results of the risk factors for uveal melanoma case-control study. J Natl Cancer Inst (2009) 0.83